1. Home
  2. INSP vs TLX Comparison

INSP vs TLX Comparison

Compare INSP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inspire Medical Systems Inc.

INSP

Inspire Medical Systems Inc.

HOLD

Current Price

$130.44

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$9.02

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INSP
TLX
Founded
2007
2015
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.3B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
INSP
TLX
Price
$130.44
$9.02
Analyst Decision
Buy
Strong Buy
Analyst Count
16
4
Target Price
$132.27
$21.00
AVG Volume (30 Days)
1.8M
115.0K
Earning Date
11-03-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
34.77
N/A
EPS
1.48
0.04
Revenue
$882,622,000.00
$664,225,558.00
Revenue This Year
$14.97
N/A
Revenue Next Year
$11.81
N/A
P/E Ratio
$88.53
$284.99
Revenue Growth
16.81
55.35
52 Week Low
$70.77
$8.76
52 Week High
$216.01
$30.36

Technical Indicators

Market Signals
Indicator
INSP
TLX
Relative Strength Index (RSI) 63.19 38.74
Support Level $132.39 $9.37
Resistance Level $147.03 $10.03
Average True Range (ATR) 8.60 0.25
MACD 0.20 -0.00
Stochastic Oscillator 62.23 7.65

Price Performance

Historical Comparison
INSP
TLX

About INSP Inspire Medical Systems Inc.

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: